Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
-
Published:2024-09
Issue:9
Volume:35
Page:805-816
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Felip E., Cho B.C., Gutiérrez V., Alip A., Besse B.ORCID, Lu S., Spira A.I., Girard N., Califano R., Gadgeel S.M., Yang J.C.-H.ORCID, Yamamoto S.ORCID, Azuma K., Kim Y.J.ORCID, Lee K.-H., Danchaivijitr P., Ferreira C.G., Cheng Y., Sendur M.A.N., Chang G.-C., Wang C.-C., Prabhash K., Shinno Y., Stroyakovskiy D., Paz-Ares L., Rodriguez-Cid J.R., Martin C., Campelo M.R.G., Hayashi H., Nguyen D.ORCID, Tomasini P., Gottfried M., Dooms C., Passaro A.ORCID, Schuler M.ORCID, Gelatti A.C.Z., Owen S., Perdrizet K., Ou S.-H.I.ORCID, Curtin J.C., Zhang J.ORCID, Gormley M., Sun T., Panchal A., Ennis M., Fennema E., Daksh M., Sethi S., Bauml J.M., Lee S.-H.
Funder
Janssen Research & Development LLC
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|